Drug Profile


Alternative Names: Antiplatelet thrombolysin for injection - Lee's Pharmaceutical; Declotana; ZK 001

Latest Information Update: 17 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lees Pharmaceutical Holdings
  • Class Antiplatelets; Ischaemic heart disorder therapies; Peptides; Snake venoms
  • Mechanism of Action Adhesion receptor antagonists; Platelet glycoprotein GPIb-IX complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thrombotic thrombocytopenic purpura
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Myocardial infarction

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 24 Mar 2016 Anfibatide receives Orphan Drug status for Thrombotic thrombocytopenic purpura in USA
  • 10 Dec 2015 Phase-II clinical trials in Myocardial infarction in China (IV) (Company pipeline, Dec 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top